Rhythm Pharmaceuticals (MEX:RYTM) Institutional Ownership: 62.69% (As of Jul. 08, 2026)


MEX:RYTM Rhythm Pharmaceuticals Inc MEX:RYTM
56 GF Score
Price MXN1,866.76
GF Value MXN1,863.92
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Institutional Ownership?

Rhythm Pharmaceuticals MEX:RYTM 56 Institutional Ownership is 62.69% as of Jul. 08, 2026. GuruFocus rates MEX:RYTM with a GF Score™ of 56/100 and a GF Value™ of MXN1,863.92. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rhythm Pharmaceuticals's institutional ownership is 62.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rhythm Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rhythm Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.22%.

Rhythm Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Institutional Ownership Chart

Rhythm Pharmaceuticals Historical Data

The historical data trend for Rhythm Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 62.38 63.01 63.38 64.88 64.20 63.37 63.95 62.11 61.87 62.69
MEX:RYTM
56GF Score
Rhythm Pharmaceuticals Inc MEX:RYTM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 62.69% mean?
Rhythm Pharmaceuticals (MEX:RYTM) has a Institutional Ownership of 62.69% as of Jul. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Institutional Ownership too high?
Rhythm Pharmaceuticals' current Institutional Ownership is 62.69%. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Institutional Ownership compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Institutional Ownership of 62.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Institutional Ownership is 62.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Institutional Ownership of 62.69%. The stock's GF Value™ is MXN1,863.92, compared to a current price of MXN1,866.76 — trading 0.2% above its estimated fair value. The current Institutional Ownership is 62.69%. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Institutional Ownership is 62.69% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,866.76 is trading 0.2% above its estimated GF Value™ of MXN1,863.92.

Key valuation signals for MEX:RYTM:

  • Institutional Ownership: 62.69%
  • GF Value™: MXN1,863.92 vs. price of MXN1,866.76 (0.2% above fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score

Get the complete analysis for MEX:RYTM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,866.76
Price
MXN1,863.92
GF Value